The facts behind niacin

Therapeutic Advances in Cardiovascular Disease

Volumn 5, Issue 5, 2011, Pages 227-240

  Hochholzer, Willibald ^a   Berg, David D ^a   Giugliano, Robert P ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cardiovascular risk; cholesterol; lipid lowering therapy; niacin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AGENTS AFFECTING LIPID METABOLISM; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLOFIBRATE; COLESTIPOL; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; LIPID METABOLISM; LIVER TOXICITY; MONOTHERAPY; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; NIACIN; RISK FACTORS;

EID: 80053065826     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944711419197     Document Type: Review

References (62)

1. Aim-High Investigators. (2011) The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic Syndrome with low HDL / high triglycerides: impact on Global Health outcomes (AIM-HIGH) Trial. Am Heart J 161: 538–543.
2. Al-Mohaissen M.A. Pun S.C. Frohlich J.J. (2010) Niacin: from mechanisms of action to therapeutic uses. Mini Rev Med Chem 10: 204–217.
3. Altschul R. Hoffer A. Stephen J.D. (1955) Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 54: 558–559.
4. Armitage J. Bowman L. Wallendszus K. Bulbulia R. Rahimi K. Haynes R. et al (2010) Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376: 1658–1669.
5. Baigent C. Blackwell L. Emberson J. Holland L.E. Reith C. Bhala N. et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681.
6. Blankenhorn D.H. Nessim S.A. Johnson R.L. Sanmarco M.E. Azen S.P. Cashin-Hemphill L. (1987) beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257: 3233–3240.
7. Brown B.G. (2006) Niaspan in the management of dyslipidaemia: the evidence. Eur Heart J Suppl 8: F60–F67.
8. Brown B.G. Zambon A. Poulin D. Rocha A. Maher V.M. Davis J.W. et al (1998) Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 81: 52B–59B.
9. Brown B.G. Zhao X.Q. Chait A. Fisher L.D. Cheung M.C. Morse J.S. et al (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583–1592.
10. Brown G. Albers J.J. Fisher L.D. Schaefer S.M. Lin J.T. Kaplan C. et al (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289–1298.
11. Canner P.L. Berge K.G. Wenger N.K. Stamler J. Friedman L. Prineas R.J. et al (1986) Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 8: 1245–1255.
12. Cannon C.P. Braunwald E. McCabe C.H. Rader D.J. Rouleau J.L. Belder R. et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504.
13. Capuzzi D.M. Guyton J.R. Morgan J.M. Goldberg A.C. Kreisberg R.A. Brusco O.A. et al (1998) Efficacy and safety of an extended-release niacin (niaspan): a long-term study. Am J Cardiol 82: 74U–81U, discussion 85U–86U.
14. Carlson L.A. Hamsten A. Asplund A. (1989) pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 226: 271–276.
15. Carlson L.A. Rosenhamer G. (1988) Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223: 405–418.
16. Cashin-Hemphill L. Mack W.J. Pogoda J.M. Sanmarco M.E. Azen S.P. Blankenhorn D.H. (1990) Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264: 3013–3017.
17. Coronary Drug Project Research Group. (1975) Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381.
18. Costanzo P. Perrone-Filardi P. Vassallo E. Paolillo S. Cesarano P. Brevetti G. et al (2010) Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 56: 2006–2020.
19. Downs J.R. Clearfield M. Weis S. Whitney E. Shapiro D.R. Beere P.A. et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS. Air Force / Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–1622.
20. Duff C.J. Hooper N.M. (2011) PCSK9: An emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets 15: 157–168.
21. Ganji S.H. Tavintharan S. Zhu D. Xing Y. Kamanna V.S. Kashyap M.L. (2004) Niacin noncompetitively inhibits DGAT 2 but not DGAT 1 activity in Hepg 2 cells. J Lipid Res 45: 1835–1845.
22. Genest J. McPherson R. Frohlich J. Anderson T. Campbell N. Carpentier A. et al (2009) 2009 Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 25: 567–579.
23. Gibbons L.W. Gonzalez V. Gordon N. Grundy S. (1995) The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 99: 378–385.
24. Graham I. Atar D. Borch-Johnsen K. Boysen G. Burell G. Cifkova R. et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 28: 2375–2414.
25. Grundy S.M. Mok H.Y. Zech L. Berman M. (1981) Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 22: 24–36.
26. Grundy S.M. Vega G.L. McGovern M.E. Tulloch B.R. Kendall D.M. Fitz-Patrick D. et al (2002) Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 162: 1568–1576.
27. Guyton J.R. Bays H.E. (2007) Safety considerations with niacin therapy. Am J Cardiol 99: 22C–31C.
28. Guyton J.R. Blazing M.A. Hagar J. Kashyap M.L. Knopp R.H. Mckenney J.M. et al (2000) Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 160: 1177–1184.
29. Guyton J.R. Goldberg A.C. Kreisberg R.A. Sprecher D.L. Superko H.R. O'Connor C.M. (1998) Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 82: 737–743.
30. Heart Protection Study Collaborative Group. (2002) MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.
31. Hussein A.A. Nicholls S.J. (2010) Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Ther Clin Risk Manag 6: 183–190.
32. Illingworth D.R. Stein E.A. Mitchel Y.B. Dujovne C.A. Frost P.H. Knopp R.H. et al (1994) Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 154: 1586–1595.
33. Jin F.Y. Kamanna V.S. Kashyap M.L. (1997) Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G 2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 17: 2020–2028.
34. Knopp R.H. (1999) Drug treatment of lipid disorders. N Engl J Med 341: 498–511.
35. Lee J.M. Robson M.D. Yu L.M. Shirodaria C.C. Cunnington C. Kylintireas I. et al (2009) Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 54: 1787–1794.
36. Lewington S. Whitlock G. Clarke R. Sherliker P. Emberson J. Halsey J. et al (2007) blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829–1839.
37. Lipid Research Clinics Program. (1984) Lipid Research Clinics Program. JAMA 252: 2545–2548.
38. Lipid Study Group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349–1357.
39. Luria M.H. (1988) Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med 148: 2493–2495.
40. Maccubbin D. Bays H.E. Olsson A.G. Elinoff V. Elis A. Mitchel Y. et al (2008) Lipid-modifying efficacy and tolerability of extended-release niacin / laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 62: 1959–1970.
41. Maccubbin D. Koren M.J. Davidson M. Gavish D. Pasternak R.C. Macdonell G. et al (2009) Flushing profile of extended-release niacin / laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 104: 74–81.
42. Martinez L.O. Jacquet S. Esteve J.P. Rolland C. Cabezon E. Champagne E. et al (2003) Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421: 75–79.
43. Mitka M. (2011) CETP inhibition shows promise as way to reduce cardiovascular disease risk. JAMA 305: 136–137.
44. Natarajan P. Ray K.K. Cannon C.P. (2010) High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 55: 1283–1299.
45. National Cholesterol Education Program. (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486–2497.
46. National Heart Lung and Blood Institute (2011) http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2792. Accessed May 27, 2011.
47. O'Leary D.H. Polak J.F. Kronmal R.A. Manolio T.A. Burke G.L. Wolfson S.K. Jr (1999) carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340: 14–22.
48. Polak, J.F., Pencina, M.J., Pencina, K.M., O'donnell, C.J., Wolf, P.A., and D'agostino, R.B., Sr. (2011) Carotid-Wall Intima-Media Thickness and Cardiovascular Events. The New England journal of medicine 365: 213–221.
49. Scandinavian Simvastatin Survival Study Group. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.
50. Shepherd J. Cobbe S.M. Ford I. Isles C.G. Lorimer A.R. Macfarlane P.W. et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301–1307.
51. Sibley C.T. Gottlieb I. Cox C. Godoy G. Spooner A.E. Bluemke D.A. et al (2009) Comparative effect of statins vs niacin on MRI measured regression of carotid atherosclerosis in a randomized clinical trial: the NIA Plaque Study. Circulation 120: S376–S37a
52. Sniderman A.D. Williams K. Contois J.H. Monroe H.M. McQueen M.J. de Graaf J. et al (2011) A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 4: 337–345.
53. Stamler J. Wentworth D. Neaton J.D. (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823–2828.
54. Taylor A.J. Sullenberger L.E. Lee H.J. Lee J.K. Grace K.A. (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512–3517.
55. Taylor A.J. Villines T.C. Stanek E.J. Devine P.J. Griffen L. Miller M. et al (2009) Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361: 2113–2122.
56. US Food and Drug Administration (FDA): http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed June 23, 2011.
57. van der Hoorn J.W. de Haan W. Berbee J.F. Havekes L.M. Jukema J.W. Rensen P.C. et al (2008) Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 28: 2016–2022.
58. Vega G.L. Grundy S.M. (1994) Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med 154: 73–82.
59. Vergeer M. Holleboom A.G. Kastelein J.J. Kuivenhoven J.A. (2010) The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res 51: 2058–2073.
60. Wilson P.W. D'Agostino R.B. Levy D. Belanger A.M. Silbershatz H. Kannel W.B. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837–1847.
61. Wu Z.H. Zhao S.P. (2009) Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes. Pharmacology 84: 282–287.
62. Zambon A. Hokanson J.E. Brown B.G. Brunzell J.D. (1999) Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99: 1959–1964.